- Home
- LFCR vs TNXP Comparison
LFCR vs TNXP Comparison
Compare LFCR & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- TNXP
- Stock Information
- Founded
- LFCR 1986
- TNXP 2007
- Country
- LFCR United States
- TNXP United States
- Employees
- LFCR N/A
- TNXP N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- LFCR Health Care
- TNXP Health Care
- Exchange
- LFCR Nasdaq
- TNXP Nasdaq
- Market Cap
- LFCR 256.6M
- TNXP 213.7M
- IPO Year
- LFCR N/A
- TNXP N/A
- Fundamental
- Price
- LFCR $7.72
- TNXP $17.59
- Analyst Decision
- LFCR Buy
- TNXP Buy
- Analyst Count
- LFCR 4
- TNXP 1
- Target Price
- LFCR $8.00
- TNXP $70.00
- AVG Volume (30 Days)
- LFCR 155.8K
- TNXP 661.7K
- Earning Date
- LFCR 11-06-2025
- TNXP 11-10-2025
- Dividend Yield
- LFCR N/A
- TNXP N/A
- EPS Growth
- LFCR N/A
- TNXP N/A
- EPS
- LFCR N/A
- TNXP N/A
- Revenue
- LFCR $128,867,000.00
- TNXP $10,299,000.00
- Revenue This Year
- LFCR $4.72
- TNXP $14.79
- Revenue Next Year
- LFCR $10.97
- TNXP $933.49
- P/E Ratio
- LFCR N/A
- TNXP N/A
- Revenue Growth
- LFCR 0.47
- TNXP N/A
- 52 Week Low
- LFCR $4.76
- TNXP $6.76
- 52 Week High
- LFCR $8.85
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- LFCR 66.09
- TNXP 35.76
- Support Level
- LFCR $6.58
- TNXP $16.10
- Resistance Level
- LFCR $7.24
- TNXP $18.96
- Average True Range (ATR)
- LFCR 0.32
- TNXP 1.02
- MACD
- LFCR 0.09
- TNXP 0.31
- Stochastic Oscillator
- LFCR 96.64
- TNXP 32.81
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.